Valuation: Syntara Limited

Market Cap 43.16M 30.26M 26.28M 24.4M 22.51M 42.39M 2.89B 289M 113M 1.43B 114M 111M 4.82B P/E 2026 *
-4.4x
P/E 2027 * -4.4x
Enterprise Value 30.26M 21.21M 18.43M 17.11M 15.78M 29.72M 2.03B 203M 79.31M 1.01B 79.66M 77.92M 3.38B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.28%
Yield 2026 *
-
Yield 2027 * -
1 week+4.76%
Current month+10.00%
1 month+10.00%
3 months-21.43%
6 months-33.33%
Current year-37.14%
1 week 0.02
Extreme 0.022
0.02
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.019
0.04
1 year 0.02
Extreme 0.019
0.07
3 years 0.01
Extreme 0.014
0.1
5 years 0.01
Extreme 0.014
0.15
10 years 0.01
Extreme 0.014
0.37
Manager TitleAgeSince
Chief Executive Officer 64 2013-03-11
Director of Finance/CFO - 2024-08-30
Chief Tech/Sci/R&D Officer - 2022-06-30
Director TitleAgeSince
Director/Board Member 64 2013-03-11
Chairman 68 2023-10-02
Director/Board Member - 2022-12-15
Date Insider Type Main position Quantity % Market Cap.
3/13/25 Buy

Director

9,753,442 0.6008%
9/24/24 Buy

Director

53,571,429 4.1513%
8/12/21 Expiration

Chief Executive Officer

471,000 0.1040%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+4.76%-63.33%-56.00% 29.89M
-0.81%-0.33%+27.15%+81.12% 55.6B
-3.74%-6.32%+42.70%+64.45% 55.2B
-0.11%+0.86%-15.63%-13.56% 23.51B
-1.58%-5.51%-3.51%+375.36% 22.35B
+2.33%-1.07%+20.12%-12.29% 20.6B
-1.23%-3.15%+26.00%-31.88% 17.45B
+1.37%-5.14%+17.21%+545.40% 15.16B
+1.16%+0.58%+51.87%+181.96% 13.91B
-5.09%-10.87%+153.11%+272.20% 13.74B
Average -0.77%-1.39%+25.57%+140.68% 23.76B
Weighted average by Cap. -1.25%-0.46%+31.04%+125.74%

Financials

2026 *2027 *
Net sales - -
Net income -12.35M -8.66M -7.52M -6.98M -6.44M -12.13M -826M -82.67M -32.37M -410M -32.51M -31.8M -1.38B -31.85M -22.33M -19.39M -18.01M -16.61M -31.28M -2.13B -213M -83.47M -1.06B -83.84M -82M -3.56B
Net Debt -12.9M -9.04M -7.85M -7.29M -6.73M -12.67M -863M -86.35M -33.81M -429M -33.96M -33.21M -1.44B -32.8M -22.99M -19.97M -18.55M -17.1M -32.22M -2.19B -220M -85.96M -1.09B -86.34M -84.45M -3.67B
Logo Syntara Limited
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing topical pan-LOX inhibitors in scar revision, keloid scarring and scar prevention post-surgery. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
Employees
-
Date Price Change Volume
26-07-30 A$0.0220 0.00% 1,188,067
26-07-29 A$0.0220 0.00% 382,811
26-07-28 A$0.0220 0.00% 529,319
26-07-27 A$0.0220 0.00% 167,427
26-07-24 A$0.0220 -8.33% 281,859
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0220AUD
Average target price
0.1050AUD
Spread / Average Target
+377.27%

Quarterly revenue - Rate of surprise